|
|
Volumn 16, Issue 4, 2002, Pages 745-747
|
|
Postremission therapy in older adults with acute myeloid leukemia: An opportunity for new drug development
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ANTIEMETIC AGENT;
ANTIFUNGAL AGENT;
ANTIINFECTIVE AGENT;
ANTIVIRUS AGENT;
CYTARABINE;
GEMTUZUMAB OZOGAMICIN;
HEMATOLOGIC AGENT;
HEMOPOIETIC GROWTH FACTOR;
HYDROXYUREA;
IMATINIB;
METOCLOPRAMIDE;
PROTEASOME INHIBITOR;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
PROTEIN TYROSINE KINASE INHIBITOR;
ACUTE GRANULOCYTIC LEUKEMIA;
ADVANCED CANCER;
AGED;
ARTICLE;
CANCER CLASSIFICATION;
CANCER RECURRENCE;
CANCER SURVIVAL;
CHRONIC MYELOID LEUKEMIA;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG SYNTHESIS;
HEMATOPOIETIC STEM CELL;
HUMAN;
LEUKEMIA REMISSION;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
TREATMENT OUTCOME;
ACUTE DISEASE;
ADULT;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BONE MARROW TRANSPLANTATION;
CLINICAL TRIALS;
DRUG DESIGN;
HUMANS;
LEUKEMIA, MYELOID;
MIDDLE AGED;
REMISSION INDUCTION;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 0036242056
PISSN: 08876924
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.leu.2402487 Document Type: Article |
|
Times cited : (4)
|
|
References (6)
|
